Related Experiment Video

Updated: Dec 25, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

963

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Youhai Jiang1,2, Xiaofang Zhao2,3, Jing Fu1,2,4

  • 1Division of Life Sciences and Medicine, Cancer Research Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.

Frontiers in Immunology
|April 1, 2020
PubMed

Insights

Immune checkpoint inhibitors like PD-1/PD-L1 blockade show promise in cancer treatment but have limited response rates. This review explores methods to predict patient response and enhance immunotherapy efficacy for better cancer precision treatment.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors, including programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade, leverage T cell activity against cancer.
  • Despite efficacy, objective response rates for PD-1/PD-L1 blockade remain low (20-30%), particularly in solid tumors, with variable side effects.
  • Numerous unknown factors impact the therapeutic effectiveness of PD-1/PD-L1 blockade, posing challenges for precise cancer treatment.

Purpose of the Study:

  • To summarize recent advancements in predicting patient response to PD-1/PD-L1 blockade.
  • To review combined therapeutic strategies aimed at improving the efficacy of PD-1/PD-L1 blockade.
  • To discuss methods and evaluations for enhancing precision immunotherapy.

Main Methods:

  • Literature review of recent progress in response prediction for PD-1/PD-L1 blockade.
  • Analysis of combined application strategies with PD-1/PD-L1 blockade.
  • Discussion of evaluation methods for improving immunotherapy implementation.

Main Results:

  • Limited objective response rates (20-30%) and side effects are associated with current PD-1/PD-L1 blockade therapies.
  • Tumor heterogeneity and other factors contribute to the low efficacy and unknown variables affecting treatment outcomes.
  • Accurate screening of responding patients and combination therapies are critical for improving treatment success.

Conclusions:

  • Predicting response and optimizing combination strategies are essential for maximizing the benefits of PD-1/PD-L1 blockade.
  • Further research into predictive biomarkers and novel therapeutic combinations is needed to enhance precision immunotherapy.
  • Improving patient selection and treatment regimens can overcome current limitations and improve outcomes in cancer immunotherapy.
Keywords:
PD-1PD-L1immunotherapypatient responseprecise treatment

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K